Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Differential expression of SKALP/Elafin in human epidermal tumors.

Literature DB >> 8256855

Differential expression of SKALP/Elafin in human epidermal tumors.

H A Alkemade¹, H O Molhuizen, I M van Vlijmen-Willems, U J van Haelst, J Schalkwijk.

Abstract

Recently we described a new epidermal serine proteinase inhibitor, skin-derived antileukoproteinase (SKALP), also known as elafin. SKALP/elafin was found to be absent in normal human epidermis, but can be induced in vitro and in vivo under hyperproliferative conditions. Here we studied the expression of SKALP/elafin in several types of epidermal tumors (basal cell carcinoma, squamous cell carcinoma, Bowen's disease, actinic keratosis, and keratoacanthoma). Using immunohistochemical staining SKALP/elafin appeared to be differentially expressed in these tumors. Functional measurements of anti-proteinase activity, and Western blotting of tumor extracts confirmed our findings at the histological level. In well differentiated squamous cell carcinoma, SKALP/elafin messenger RNA was demonstrated by non-radioactive in situ hybridization. We conclude that SKALP/elafin is a marker for abnormal or disturbed squamous differentiation. A possible role of SKALP/elafin in the control of tumor cell invasion is discussed.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1993 PMID： 8256855 PMCID： PMC1887253

Source DB: PubMed Journal: Am J Pathol ISSN： 0002-9440 Impact factor: 4.307

46 in total

1. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.

Authors: P H Quax; R T van Leeuwen; H W Verspaget; J H Verheijen
Journal: Cancer Res Date: 1990-03-01 Impact factor: 12.701

Review 2. Metastasis suppressor genes.

Authors: L A Liotta; W Stetler-Stevenson; P S Steeg
Journal: Important Adv Oncol Date: 1991

3. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis.

Authors: J Schalkwijk; A Chang; P Janssen; G J De Jongh; P D Mier
Journal: Br J Dermatol Date: 1990-05 Impact factor: 9.302

4. An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization.

Authors: K Hochstrasser; G J Albrecht; O L Schönberger; B Rasche; K Lempart
Journal: Hoppe Seylers Z Physiol Chem Date: 1981-10

5. Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors: L Ossowski; E Reich
Journal: Cell Date: 1983-12 Impact factor: 41.582

6. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo.

Authors: J Grøndahl-Hansen; L R Lund; E Ralfkiaer; V Ottevanger; K Danø
Journal: J Invest Dermatol Date: 1988-06 Impact factor: 8.551

7. Immunohistochemical localization of SKALP/elafin in psoriatic epidermis.

Authors: J Schalkwijk; I M van Vlijmen; J A Alkemade; G J de Jongh
Journal: J Invest Dermatol Date: 1993-04 Impact factor: 8.551

8. Differential protease expression by cutaneous squamous and basal cell carcinomas.

Authors: A P Sappino; D Belin; J Huarte; S Hirschel-Scholz; J H Saurat; J D Vassalli
Journal: J Clin Invest Date: 1991-10 Impact factor: 14.808

9. Migrating keratinocytes express urokinase-type plasminogen activator.

Authors: S Morioka; G S Lazarus; J L Baird; P J Jensen
Journal: J Invest Dermatol Date: 1987-04 Impact factor: 8.551

10. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.

Authors: P H Quax; G N van Muijen; E J Weening-Verhoeff; L R Lund; K Danø; D J Ruiter; J H Verheijen
Journal: J Cell Biol Date: 1991-10 Impact factor: 10.539

11 in total

1. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Authors: Huafeng Wei; Karl Erik Hellström; Ingegerd Hellström
Journal: Gynecol Oncol Date: 2012-03-16 Impact factor: 5.482

2. Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease.

Authors: Marie-Charlotte Brüggen; Peter Petzelbauer; Hildegard Greinix; Emmanuel Contassot; Dragana Jankovic; Lars French; Gérard Socié; Werner Rabitsch; Zoya Kuzmina; Peter Kalhs; Robert Knobler; Georg Stingl; Georg Stary
Journal: J Invest Dermatol Date: 2014-11-18 Impact factor: 8.551

3. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.

Authors: Joseph A Caruso; Kelly K Hunt; Khandan Keyomarsi
Journal: Cancer Res Date: 2010-09-07 Impact factor: 12.701

4. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Authors: Adam Clauss; Vivian Ng; Joyce Liu; Huiying Piao; Moises Russo; Natalie Vena; Qing Sheng; Michelle S Hirsch; Tomas Bonome; Ursula Matulonis; Azra H Ligon; Michael J Birrer; Ronny Drapkin
Journal: Neoplasia Date: 2010-02 Impact factor: 5.715

5. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.

Authors: Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240